Whalesbook
📉 The Financial Deep Dive
Amanta Healthcare Limited has presented a compelling financial narrative, showcasing a remarkable turnaround from previous losses to robust profitability. For the nine months ended December 31, 2025 (9M FY26), the company reported revenue of INR 211 Cr, a 3.97% year-on-year (YoY) increase. EBITDA for the period stood at INR 45 Cr, with margins improving 42 basis points YoY to 21.31%. The most striking improvement was in Profit After Tax (PAT), which surged 51.3% YoY to INR 9 Cr, while PAT margins expanded 139 basis points to 4.43%. This momentum continued into Q3 FY26, with revenue growing 9.8% YoY to INR 75 Cr and PAT increasing 8.1% YoY to INR 5 Cr.
Annually, the company demonstrated a strong recovery in FY25, posting a PAT of INR 11 Cr, a significant shift from net losses of INR 2 Cr in FY23 and INR 4 Cr in FY24. This profitability boost is underpinned by strategic cost-saving measures and operational efficiencies.
📊 Quality of Earnings & Balance Sheet Strength
The quality of Amanta Healthcare's financial performance is bolstered by significant deleveraging. Total borrowings were reduced by over INR 30 Cr, primarily through the repayment of Non-Convertible Debentures. This has dramatically improved the Debt-to-Equity ratio from 1.19x in FY23 to a healthy 0.44x in FY25. Net worth has also seen a healthy uptick, reaching INR 96 Cr in FY25 from INR 66 Cr in FY24, supported by retained earnings and a ₹20 Cr equity infusion via private placement. Capital Work-in-Progress (CWIP) has increased, reflecting ongoing investments in future growth.
🚀 Outlook & Growth Drivers
Amanta Healthcare has outlined an aggressive growth strategy, targeting a Revenue CAGR of over 20% and EBITDA Margins exceeding 25% over the next two years. Key catalysts include the scaling up of Large Volume Parenterals (LVP) and Small Volume Parenterals (SVP) capacities, slated for commissioning in FY27. The company plans to expand its product portfolio into complex dosages and niche molecules across therapeutic areas like anti-infectives and respiratory care. A significant strategic initiative is the implementation of a 10.8 MW captive solar power plant, projected to reduce annual power costs by INR 9 Cr, directly boosting EBITDA margins. The focus on expanding presence in regulated markets like the UK, alongside serving emerging markets, is also a crucial growth avenue.
🚩 Risks & Forward View
While the outlook is positive, execution risks associated with the timely commissioning and ramp-up of new capacities, along with successful penetration into competitive regulated markets, will be key to watch. The company has planned a substantial Capital Expenditure (CapEx) of INR 130 Cr for FY26P, signaling a strong commitment to its expansion plans. Investors will closely monitor the progress on EBITDA margin expansion and revenue growth trajectory in the upcoming quarters.